science

MDX-1097

MDX-1097 is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand MDX-1097 rather than just read about it. In short: MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma. In 2023 it was assessed in a Phase IIb clinical trial in conjunction with lenalidomide and dexamethasone as a treatment for multiple myeloma, a type of white blood cell cancer.

Key takeaways

MDX-1097 belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect MDX-1097 to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of MDX-1097 from memory before moving on to harder problems.

Reference excerpt

MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma. In 2023 it was assessed in a Phase IIb clinical trial in conjunction with lenalidomide and dexamethasone as a treatment for multiple myeloma, a type of white blood cell cancer. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Ltd acquired the rights to MDX-1097 and are taking it through clinical testing.

Development Originally, a mouse (murine) antibody was used for initial experiments. This murine monoclonal antibody, called K-1-21, was raised against purified human kappa Bence Jones proteins (BJP). K-1-21 was shown to be specific for a cell-surface antigen that was named kappa myeloma antigen (KMA). KMA was found on malignant B cells (plasma cells) isolated from the bone marrow of patients with kappa restricted multiple myeloma (kMM), lymphoma and Waldenström macroglobulinemia. KMA was also detected in cell culture on the surface of human myeloma cell lines derived from patients with kappa restricted myeloma (kHMCLs). The K-1-21 antibody was re-named mKap. The next step was to produce an antibody for use in humans that was based on the murine version. The heavy and light chain variable region genes (VH and Vk) of MDX-1097 were isolated from mKap hybridoma cells using recombinant DNA methodologies. MDX-1097, a chimeric (murine plus human) monoclonal antibody, was manufactured according by Medarex Inc. (subsidiary of Bristol-Myers Squibb). MDX-1097 has retained the specificity and affinity observed for mKap. MDX-1097 has been used in the clinical trials described below, as well as in vitro studies.

Pharmacology

Mechanism of action KMA is a membrane-bound form of free kappa light chain on malignant B-cells, in-vitro activated B cells and rare tonsillar B-cells. KMA is not found on normal human leucocytes. KappaMab (MDX-1097) is specific for KMA and binds to a unique conformational epitope in the kappa constant region that is presented when kappa free light chain (kFLC) associates with sphingomyelin in the cell membrane. KappaMab does not bind to kappa immunoglobulin (Igκ) and it has a 5-fold higher affinity for membrane-bound KMA (IC50 4nM) when compared to serum kappa Free Light Chain (IC50 20nM). Moreover, in vitro studies demonstrated that KM induces selective antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) of kappa-positive MM cells and that lenalidomide (LEN) exposure upregulates KMA expression on MM cells promoting enhanced KM-induced NK-mediated ADCC.

Clinical trials In an initial Phase 1 clinical trial, MDX-1097 was administered intravenously to multiple myeloma patients with stable kappa-type disease, with doses ranging from 0.3 mg/kg to 10.0 mg/kg. The study primarily aimed to evaluate MDX-1097's safety profile across these dose levels. In a Phase 2a clinical trial involving 19 patients with stable kappa-type multiple myeloma, MDX-1097 was administered at a dose of 10 mg/kg weekly for 8 doses to assess safety and efficacy., In a Phase 2b investigator-initiated clinical trial, repeated doses of KappaMab were administered either alone or in combination with lenalidomide and dexamethasone to patients with kappa-type relapsed, refractory multiple myeloma (MM). The study, conducted across multiple centers, aimed to assess safety and efficacy in both treatment cohorts. In 2026, the Peter MacCallum Cancer Centre opened the KOALA trial, a first-in-human study evaluating the safety and efficacy of KMCAR — a chimeric antigen receptor T-cell therapy that uses the binding domain of KappaMab — in patients with multiple myeloma.

References

Worked examples

Example 1 — a first encounter with MDX-1097

Start with the simplest possible case. Write down what MDX-1097 claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to MDX-1097 before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about MDX-1097 ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of MDX-1097

In research: MDX-1097 appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses MDX-1097 in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: MDX-1097 is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies for tumors, so understanding it makes those chapters shorter.
In everyday life: Look for MDX-1097 outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “MDX-1097” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study MDX-1097 in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what MDX-1097 means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain MDX-1097 out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is MDX-1097 in simple terms?

Why does MDX-1097 matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study MDX-1097?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on MDX-1097.